Literature DB >> 16039289

Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL, and LDL from normolipidemic humans.

Hannia Campos1, Christina Khoo, Frank M Sacks.   

Abstract

Smaller size particles of intestinal origin may be more relevant to atherosclerosis than larger particles because of easier transendothelial transport. We examined the diurnal pattern in response to low-fat high-carbohydrate meals and the effect of a single high-fat milkshake on apoB-48 in very light Sf degrees >400, light Sf degrees 60-400, and dense Sf degrees 20-60 VLDL, IDL, and LDL in 24 subjects (12 in each study). After the high-fat meal, apoB-48 concentrations peaked at 3 h for very light VLDL, 4 h for light VLDL, and 5 h for dense VLDL and IDL, suggesting a delipidation cascade. The diurnal pattern was characterized by a sharp increase in light and dense VLDL apoB-48 after breakfast, reaching the highest concentration 4-8h after breakfast. Less response was observed after lunch, dinner or snack, despite 75% of energy supplied by these meals. The proportion of apoB-48 in LDL in the fasting state ranged between 48 and 54%. LDL apoB-48 concentration decreased by 35% after the high-fat meal, and slowly recovered to near fasting concentrations after 10-12 h. In contrast, in the diurnal study, LDL apoB-48 concentration steady increased peaking 13 h after breakfast, followed by a sharp decrease. In sum, most intestinally synthesized apoB lipoproteins circulate in LDL, and are likely formed in the late postprandial period from larger VLDL-size particles. Although small apoB-48 lipoproteins may be atherogenic remnant particles, their very low concentration may diminish their clinical significance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039289     DOI: 10.1016/j.atherosclerosis.2004.12.045

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  18 in total

Review 1.  Circadian clocks in the digestive system.

Authors:  Anneleen Segers; Inge Depoortere
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-02       Impact factor: 46.802

2.  Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat.

Authors:  Chunyu Zheng; Katsunori Ikewaki; Brian W Walsh; Frank M Sacks
Journal:  J Lipid Res       Date:  2006-05-09       Impact factor: 5.922

3.  Serum Lipid Profile: Fasting or Non-fasting?

Authors:  P K Nigam
Journal:  Indian J Clin Biochem       Date:  2010-12-29

4.  Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects.

Authors:  Seiko Otokozawa; Masumi Ai; Margaret R Diffenderfer; Bela F Asztalos; Akira Tanaka; Stefania Lamon-Fava; Ernst J Schaefer
Journal:  Metabolism       Date:  2009-07-09       Impact factor: 8.694

Review 5.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef
Journal:  J Clin Endocrinol Metab       Date:  2012-09       Impact factor: 5.958

Review 6.  A Systematic Review and Meta-analysis of the Effect of Gastric Bypass Surgery on Plasma Lipid Levels.

Authors:  Kirstin A Carswell; Ajay P Belgaumkar; Stephanie A Amiel; Ameet G Patel
Journal:  Obes Surg       Date:  2016-04       Impact factor: 4.129

7.  Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels.

Authors:  Seiko Otokozawa; Masumi Ai; Thomas Van Himbergen; Bela F Asztalos; Akira Tanaka; Evan A Stein; Peter H Jones; Ernst J Schaefer
Journal:  Atherosclerosis       Date:  2008-11-12       Impact factor: 5.162

Review 8.  Triglyceride Treatment in the Age of Cholesterol Reduction.

Authors:  Nidhi Agrawal; Patricia Freitas Corradi; Namrata Gumaste; Ira J Goldberg
Journal:  Prog Cardiovasc Dis       Date:  2016-08-17       Impact factor: 8.194

9.  Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events.

Authors:  Samia Mora; Nader Rifai; Julie E Buring; Paul M Ridker
Journal:  Circulation       Date:  2008-08-18       Impact factor: 29.690

10.  Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III.

Authors:  Doris T Chan; Gursharan K Dogra; Ashley B Irish; Esther M Ooi; P Hugh Barrett; Dick C Chan; Gerald F Watts
Journal:  J Lipid Res       Date:  2009-06-21       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.